NEW YORK, May 30, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in UnitedHealth Group Incorporated ("UnitedHealth Group Incorporated" or the "Company") (NYSE: UNH) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of UnitedHealth Group Incorporated investors who were adversely affected by alleged securities fraud between December 3, 2024 and April 16, 2025. Follow the link below to get more information and be contacted by a member of our tea ...

Core Insights - The Motley Fool aims to make the world smarter, happier, and richer through its financial services [1] Company Overview - Founded in 1993, The Motley Fool is a financial services company [1] - The company reaches millions of people monthly through various channels including premium investing solutions, free guidance, market analysis on Fool.com, top-rated podcasts, and its non-profit foundation [1]

Company Performance - UnitedHealth Group (UNH) closed at $298.17, reflecting a slight increase of +0.02% from the previous trading day's closing, but lagged behind the S&P 500's daily gain of 0.4% [1] - Over the past month, shares of UnitedHealth Group have decreased by 27.55%, while the Medical sector has lost 3.41% and the S&P 500 has gained 6.69% [1] Earnings Forecast - UnitedHealth Group is projected to report earnings of $5.47 per share, indicating a year-over-year decline of 19.56% [2] - Revenue is expected to reach $112.14 billion, showing a 13.44% increase compared to the same quarter last year [2] Annual Estimates - For the entire year, earnings are forecasted at $23.38 per share, reflecting a decrease of 15.47%, while revenue is estimated at $451.8 billion, indicating an increase of 12.87% compared to the previous year [3] - Recent changes to analyst estimates suggest evolving short-term business trends, with positive revisions indicating analyst optimism about the company's profitability [3] Stock Performance and Valuation - The Zacks Rank system currently rates UnitedHealth Group as 5 (Strong Sell), with the consensus EPS estimate moving 13.7% lower over the last 30 days [5] - UnitedHealth Group has a Forward P/E ratio of 12.75, which aligns with the industry average, and a PEG ratio of 1.17, compared to the industry average PEG ratio of 0.97 [6] Industry Context - The Medical - HMOs industry, part of the Medical sector, holds a Zacks Industry Rank of 89, placing it in the top 37% of over 250 industries [7] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [7]

Group 1 - The Portnoy Law Firm is advising investors of UnitedHealth Group Incorporated regarding a class action for securities purchased between December 3, 2024, and April 16, 2025, with a deadline for filing a lead plaintiff motion by July 7, 2025 [1] - A criminal investigation by the U.S. Department of Justice into UnitedHealth Group is ongoing, focusing on potential Medicare fraud related to the company's Medicare Advantage business practices, which has been under investigation since at least summer 2024 [3] - UnitedHealth announced on May 13, 2025, that it was withdrawing its previously revised financial guidance from April 17, 2025, and disclosed a leadership change with CEO Andrew Witty stepping down and being succeeded by Chairman Stephen Hemsley [4]

Core Viewpoint - UnitedHealth Group is facing significant scrutiny and legal challenges following allegations of undisclosed payments to nursing homes aimed at reducing hospital transfers, which has led to concerns about patient care and corporate practices [1][3][4]. Group 1: Allegations and Legal Issues - Allegations have emerged that UnitedHealth incentivized nursing facilities to limit hospitalizations among Medicare Advantage enrollees, potentially compromising patient care [3][4]. - The company is currently involved in a securities fraud class action lawsuit, with claims that it improperly denied health coverage to enhance profits, leading to regulatory scrutiny [5][6]. - A significant drop in UnitedHealth's stock price occurred after the company reduced its financial guidance for 2025, attributing it to unexpected increases in care activity within its Medicare Advantage business [6][7]. Group 2: Management and Regulatory Scrutiny - The abrupt departure of CEO Andrew Witty on May 13, 2025, has added to the turmoil within the company, resulting in a more than 10% decline in share price on that day [7]. - Federal authorities are investigating whether UnitedHealth engaged in "upcoding," a practice that could inflate Medicare payments by misrepresenting patient diagnoses [8]. Group 3: Investigations and Responses - Hagens Berman, a law firm, is investigating the securities fraud claims against UnitedHealth and is encouraging investors who have suffered losses to come forward [2][9]. - The firm has raised concerns about the implications of the recent allegations on UnitedHealth's commitment to patient care and transparency [10].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of UnitedHealth Group Incorporated regarding a class action lawsuit due to allegations of misleading statements and corporate misconduct during a specified class period [1][3]. Summary by Relevant Sections Allegations - The complaint alleges that UnitedHealth engaged in a corporate strategy of denying health coverage to increase profits and share price [3]. - This strategy led to regulatory scrutiny and public outrage, culminating in the murder of Brian Thompson, which further fueled animosity towards the company [3]. - Following the murder, there was significant public backlash against UnitedHealth, with many Americans expressing support for the accused killer and demanding changes in the company's practices [3]. - Despite the changing corporate environment, UnitedHealth continued to adhere to its previous guidance, which was deemed unrealistic [3]. - The allegations assert that the defendants' public statements were materially false and misleading throughout the relevant period [3]. Class Action Details - The class period for the lawsuit is defined as December 3, 2024, to April 16, 2025 [3]. - Shareholders are encouraged to register for the class action by the deadline of July 7, 2025, to potentially become lead plaintiffs [4]. - Registration allows shareholders to receive updates on the case's progress through a portfolio monitoring software [4]. Firm Background - The Gross Law Firm is recognized nationally for its commitment to protecting investors' rights against deceit and illegal business practices [5]. - The firm aims to ensure that companies engage in responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [5].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of UnitedHealth Group Incorporated regarding a class action lawsuit alleging that the company engaged in misleading practices that harmed investors [1][2]. Allegations - The complaint claims that UnitedHealth had a corporate strategy of denying health coverage to increase profits and share price [1]. - This strategy led to regulatory scrutiny and public outrage, culminating in the murder of Brian Thompson, which further damaged the company's reputation [1]. - Following the incident, there was significant public animosity towards UnitedHealth, with many Americans expressing support for the accused killer and demanding changes in the company's practices [1]. - Despite the backlash, UnitedHealth continued to provide unrealistic guidance the day before Thompson's murder, which was inconsistent with its changing corporate strategies [1]. - The allegations assert that the defendants' public statements were materially false and misleading throughout the relevant period [1]. Class Action Details - The class period for the lawsuit is from December 3, 2024, to April 16, 2025, with a deadline for shareholders to register as lead plaintiffs by July 7, 2025 [2]. - Shareholders who register will receive updates on the case through portfolio monitoring software [2]. - Participation in the case incurs no cost or obligation for shareholders [2]. Firm's Mission - The Gross Law Firm aims to protect investors' rights against deceit and illegal business practices, ensuring companies adhere to responsible business conduct [3].

Core Insights - UnitedHealth Group's stock has declined over 50% since April 2025, prompting scrutiny into its revenue generation and key segments [1][13][15] Revenue Generation - UnitedHealth Group operates two primary businesses: UnitedHealthcare and Optum, with revenue generation roughly balanced between the two. In 2024, Optum accounted for 46% of total revenues, while UnitedHealthcare contributed 54% [2][13] - Optum's contribution to overall sales has been increasing, rising from 41% in 2021 to 46% in 2024, while UnitedHealthcare's share decreased from 59% to 54% during the same period [2] UnitedHealthcare Segment - The UnitedHealthcare segment focuses on providing a full range of health benefits and insurance products, currently facing pressure on profit margins due to rising medical costs [3][15] - The Medicare & Retirement division, which serves individuals aged 65 and older, generated $139.5 billion in revenue and $8.4 billion in EBITDA in 2024, representing 25% of the company's total revenue and 23% of its EBITDA. This segment is currently under criminal investigation for possible fraud [4][15] - The Employer & Individual segment generated $74.5 billion in gross revenue and $4.5 billion in EBITDA in 2024, accounting for 13% of the company's revenue and 12% of its total EBITDA [5] - The Community & State division reported $80.6 billion in revenue and $4.9 billion in EBITDA in 2024, making up 15% of the company's total revenue and 13% of its EBITDA [7] - The International segment generated $3.7 billion in revenue with EBITDA of approximately $222 million in 2024, accounting for less than 1% of the company's sales and profits [8] Optum Segment - Optum focuses on modernizing the healthcare system through technology and direct care delivery, with three key sub-segments: Optum Health, Optum Insight, and Optum Rx [9] - Optum Health generated $105.4 billion in gross revenue in 2024, with sales rising at an average rate of 25% since 2021, contributing 24% of the company's total EBITDA [10] - Optum Insight, focusing on data and analytics for the healthcare industry, generated $18.8 billion in sales and $3.6 billion in EBITDA, contributing 9% of the company's total EBITDA [11] - Optum Rx, a pharmacy benefit manager, generated $133.2 billion in gross revenue and $6.8 billion in EBITDA in 2024, accounting for 24% of the company's overall revenues and 18% of total EBITDA [12] Strategic Challenges - UnitedHealth Group is at a pivotal moment, facing scrutiny that impacts its stock and necessitates strategic shifts. Optum's increasing contribution to sales highlights its role in future growth, but challenges include potential political changes affecting the PBM landscape and the ongoing criminal investigation into Medicare fraud [13][15]

Core Insights - BAD BEAT Investing, led by Quad 7 Capital, has been providing investment opportunities for nearly 12 years, with a notable call in February 2020 to sell everything and go short, maintaining an average position of 95% long and 5% short since May 2020 [1] - The team consists of 7 analysts with diverse expertise in business, policy, economics, mathematics, game theory, and sciences, focusing on both long and short trades [1] - The investment strategy emphasizes short- and medium-term investments, income generation, special situations, and momentum trades, aiming to educate investors on becoming proficient traders [1] Benefits of BAD BEAT Investing - Investors can learn to understand market dynamics, execute well-researched trade ideas weekly, and utilize 4 chat rooms for discussions [2] - Daily complimentary summaries of key analyst upgrades and downgrades are provided, along with education on basic options trading and access to extensive trading tools [2]

Core Viewpoint - UnitedHealth Group Inc. has experienced a significant decline in stock value, reaching its most oversold levels since the 2008 financial crisis, with a year-to-date drop of 42% and a 30% decrease in the past month [1][2]. Technical Analysis - The stock is trading well below its eight-day, 20-day, 50-day, and 200-day simple moving averages (SMA), indicating a strong bearish trend. Current stock price is $293.58, compared to a 200-day SMA of $526.44, a 50-day SMA of $446.43, and a 20-day SMA of $348.43 [2]. - The Relative Strength Index (RSI) is at 26.75, indicating oversold conditions, while the Moving Average Convergence Divergence (MACD) is at a negative 45.29, highlighting the severity of the downtrend [3]. Market Sentiment - Hedge fund activity shows a split sentiment; Citadel Advisors reduced its stake by over 50%, selling nearly 800,000 shares, while Ken Fisher of Fisher Asset Management increased his position by nearly 53%, acquiring 1.82 million shares [4]. Company Fundamentals - Despite the stock's poor performance, UnitedHealth's vertically integrated model, combining insurance and services, continues to provide operational leverage. The company added a record 700,000 new clients in the latest quarter [5]. - The valuation stands at 12.8 times forward earnings, which some analysts believe is attractive given the company's fundamentals [5]. Contrarian Perspective - While technical indicators suggest a bearish outlook, some analysts see potential for a contrarian rebound, citing oversold signals not seen in 16 years, contingent on improving fundamentals and regulatory conditions [6].